GlassScriptPhysician profile
Ala Nijim
NPI 1356683189
$4,570.92
in general payments reported to CMS, 2019-2025
28 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $372 · 2021: $656 · 2022: $491 · 2023: $479 · 2024: $1,148 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,178.41 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $787.77 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Insmed, INC. | $565.64 | 2020-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.16 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $250.37 | 2021-2025 | |
| Baxter Healthcare | $196.28 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $170.80 | 2021-2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $139.28 | 2023-2024 | Yupelri |
| Grifols USA, LLC | $106.38 | 2024-2025 | Prolastin-C Liquid |
| Amgen INC. | $86.71 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $61.45 | 2020-2025 | Dupixent |
| Electromed, INC. | $58.09 | 2024 | Smartvest |
| Tactile Systems Technology INC | $58.08 | 2024 | Flexitouch Plus, Entre Plus |
| Gilead Sciences, INC. | $57.03 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $48.25 | 2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $44.98 | 2025 | Vest Therapy Und |
| Shionogi INC | $42.81 | 2022-2023 | Fetroja |
| Merck Sharp & Dohme LLC | $39.27 | 2020-2022 | |
| Pfizer INC. | $34.56 | 2021 | |
| United Therapeutics Corporation | $32.02 | 2019-2023 | Tyvaso |
| Vifor Pharma, INC. | $28.05 | 2024 | Veltassa |
| Jazz Pharmaceuticals INC. | $25.27 | 2024 | |
| Paratek Pharmaceuticals, INC. | $23.49 | 2025 | Nuzyra |
| Genentech USA, INC. | $22.28 | 2024 | Xolair |
| Mallinckrodt Hospital Products INC. | $21.51 | 2023 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $17.42 | 2024 | Cuvitru |
| Olympus America INC. | $16.23 | 2023 | Spin Vision Scope, 4.0mm Od, 2.0mm Wc |
| Inspire Medical Systems, INC. | $13.33 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ala Nijim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.